Ionis Pharmaceuticals (IONS) stock is back in focus after partner Biogen released topline Phase 2 CELIA data for diranersen in early Alzheimer’s disease, highlighting biomarker and cognitive signals despite a missed primary endpoint.

The CELIA update has arrived after a period where the share price has cooled from its highs, with a 90 day share price return that fell 10.69%, even as the 1 year total shareholder return sits at 129.11%. This suggests longer term holders have still seen a very strong gain while shorter term momentum has faded somewhat.

If this Alzheimer’s readout has you thinking about where the next big therapeutic shift might come from, it could be worth scanning other healthcare focused AI opportunities via the 34 healthcare AI stocks.

Ionis stock is up 129.11% over the past year but down 10.69% over the past 90 days. With shares trading at a discount to both analyst and intrinsic value estimates, is this an undervalued RNA player or a market that has already priced in future growth potential?

Most Popular Narrative: 21.9% Undervalued

Ionis Pharmaceuticals' most followed valuation narrative pegs fair value at $96.73 per share versus the last close at $75.56, framing a meaningful valuation gap for investors to weigh.

The rapid revenue growth and positive launch trajectory for Tryngolza in familial chylomicronemia syndrome (FCS), along with the imminent launch of Donidalorsen for HAE and multiple late-stage pipeline assets reading out or launching by 2027, are set to drive sustained, stepwise increases in top-line revenue and operating leverage as Ionis transitions from R&D-heavy to commercial-stage. Expanding addressable patient populations from rare diseases to larger segments like severe hypertriglyceridemia (sHTG), combined with favorable physician feedback and significant unmet need, position Ionis to capture substantial market share and revenue growth from trends tied to the rise in chronic disease and an aging population.

Want the full story behind that valuation gap? The narrative leans on ambitious revenue growth, shifting margins and a profit profile that looks very different from today. The key is how those moving parts stack up over the next few years.

Result: Fair Value of $96.73 (UNDERVALUED)

However, this setup still cuts both ways. Any regulatory delay around olezarsen or slower than expected rare disease patient identification could quickly dent the bullish case.

Another View: Sales Multiple Flags Rich Pricing

While the popular narrative leans on a 21.9% undervaluation, Ionis trades on a P/S ratio of 11.8x. That sits above the US Biotechs industry at 10.7x, above peers at 4.3x, and well ahead of a 4.7x fair ratio. This points to meaningful valuation risk if enthusiasm cools.

Next Steps

With such a mixed setup across valuation, growth hopes and pipeline risk, it makes sense to move quickly and stress test the numbers yourself using the 2 key rewards.

Looking for more investment ideas?

If you stop with one stock, you risk missing other opportunities. Use the screener to uncover fresh ideas that fit what you are really looking for.

• Target resilient income by checking out companies in the 10 dividend fortresses that might suit a cash flow focused portfolio.
• Hunt for potential mispriced opportunities by scanning the screener containing 21 high quality undiscovered gems that the broader market may not be watching yet.
• Dial down portfolio risk by concentrating on the 67 resilient stocks with low risk scores to see which stocks line up with a steadier approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.